304 related articles for article (PubMed ID: 19933918)
1. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.
Kutikov A; Egleston BL; Wong YN; Uzzo RG
J Clin Oncol; 2010 Jan; 28(2):311-7. PubMed ID: 19933918
[TBL] [Abstract][Full Text] [Related]
2. Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model.
Kutikov A; Egleston BL; Canter D; Smaldone MC; Wong YN; Uzzo RG
J Urol; 2012 Dec; 188(6):2077-83. PubMed ID: 23083850
[TBL] [Abstract][Full Text] [Related]
3. Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma.
Lughezzani G; Sun M; Budäus L; Thuret R; Perrotte P; Karakiewicz PI
J Clin Oncol; 2010 Jun; 28(18):e299-300; author reply e301. PubMed ID: 20479402
[No Abstract] [Full Text] [Related]
4. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer.
Yang L; Shen W; Sakamoto N
J Clin Oncol; 2013 Feb; 31(4):468-74. PubMed ID: 23270002
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
Zheng W; Zhu W; Yu S; Li K; Ding Y; Wu Q; Tang Q; Zhao Q; Lu C; Guo C
BMC Cancer; 2020 Nov; 20(1):1066. PubMed ID: 33148204
[TBL] [Abstract][Full Text] [Related]
6. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis.
Scoll BJ; Wong YN; Egleston BL; Kunkle DA; Saad IR; Uzzo RG
J Urol; 2009 Feb; 181(2):506-11. PubMed ID: 19084868
[TBL] [Abstract][Full Text] [Related]
7. Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis.
Li J; Zheng Q; Zhao X; Zhao J; An T; Wu M; Wang Y; Zhuo M; Zhong J; Yang X; Jia B; Chen H; Dong Z; Wang J; Chi Y; Zhai X; Wang Z
BMC Cancer; 2020 Aug; 20(1):793. PubMed ID: 32838776
[TBL] [Abstract][Full Text] [Related]
8. The first competing risk survival nomogram in patients with papillary renal cell carcinoma.
Su X; Hou NN; Yang LJ; Li PX; Yang XJ; Hou GD; Gao XL; Ma SJ; Guo F; Zhang R; Zhang WH; Qin WJ; Wang FL
Sci Rep; 2021 Jun; 11(1):11835. PubMed ID: 34088935
[TBL] [Abstract][Full Text] [Related]
9. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
[TBL] [Abstract][Full Text] [Related]
10. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma.
Tan MH; Li H; Choong CV; Chia KS; Toh CK; Tang T; Tan PH; Wong CF; Lau W; Cheng C
Cancer; 2011 Dec; 117(23):5314-24. PubMed ID: 21567386
[TBL] [Abstract][Full Text] [Related]
11. Importance of comorbidity in competing risks analysis in patients with localized renal cell carcinoma.
Lagro J; Melis RJ; Olde Rikkert MG
J Clin Oncol; 2010 Jun; 28(18):e298; author reply e301. PubMed ID: 20479414
[No Abstract] [Full Text] [Related]
12. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.
Shi L; He Y; Liu C; Qian X; Wang Z
Cancer Med; 2020 Nov; 9(21):7988-8003. PubMed ID: 32888392
[TBL] [Abstract][Full Text] [Related]
13. Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage I Non-Small-Cell Lung Cancer: A Competing Risk Analysis.
Zhou H; Zhang Y; Qiu Z; Chen G; Hong S; Chen X; Zhang Z; Huang Y; Zhang L
Clin Lung Cancer; 2018 Mar; 19(2):e195-e203. PubMed ID: 29153966
[TBL] [Abstract][Full Text] [Related]
14. A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
[TBL] [Abstract][Full Text] [Related]
15. A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.
Wu X; Yu W; Petersen RH; Sheng H; Wang Y; Lv W; Hu J
BMC Cancer; 2020 May; 20(1):429. PubMed ID: 32416716
[TBL] [Abstract][Full Text] [Related]
16. Predictive Nomogram for Midterm to Long-Term Prognosis in Patients with Papillary Renal Cell Carcinoma Based on Data from the Surveillance, Epidemiology, and End Results (SEER) Program.
Wang H; Chen X; Zhao J; Kang M; Dong R; Wang K; Qu Y
Med Sci Monit; 2020 Jun; 26():e921859. PubMed ID: 32570266
[TBL] [Abstract][Full Text] [Related]
17. Impact of age on the cancer-specific survival of patients with localized renal cell carcinoma: martingale residual and competing risks analysis.
Cai M; Wei J; Zhang Z; Zhao H; Qiu Y; Fang Y; Gao Z; Cao J; Chen W; Zhou F; Xie D; Luo J
PLoS One; 2012; 7(10):e48489. PubMed ID: 23119034
[TBL] [Abstract][Full Text] [Related]
18. Comorbidities and causes of death in the management of localized T1a kidney cancer.
Patel HD; Kates M; Pierorazio PM; Gorin MA; Jayram G; Ball MW; Hyams ES; Allaf ME
Int J Urol; 2014 Nov; 21(11):1086-92. PubMed ID: 24931430
[TBL] [Abstract][Full Text] [Related]
19. Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.
Hsiao W; Herrel LA; Yu C; Kattan MW; Canter DJ; Carthon BC; Ogan K; Master VA
Int J Urol; 2015 Mar; 22(3):264-70. PubMed ID: 25428139
[TBL] [Abstract][Full Text] [Related]
20. A novel preoperative model to predict 90-day surgical mortality in patients considered for renal cell carcinoma surgery.
Calaway AC; Monn MF; Bahler CD; Cary C; Boris RS
Urol Oncol; 2018 Oct; 36(10):470.e11-470.e17. PubMed ID: 30274725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
